InnoCan Pharma (TSE:INNO) has released an update.
InnoCan Pharma has announced a significant regulatory milestone with the FDA setting a meeting to discuss the company’s LPT-CBD technology for chronic pain treatment. The technology promises a breakthrough in non-opioid pain management with a single monthly injection, which has shown promising results in preclinical trials. The FDA consultation will be crucial for InnoCan to begin human clinical trials and address the opioid crisis with this novel treatment.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
